Russ Conroy

Data from the ASC4FIRST trial support the accelerated approval of asciminib in this CML population.

Data from the AcceleRET-Lung trial show an imbalanced risk of severe and fatal infection with pralsetinib for patients with RET fusion-positive NSCLC.

James R. Berenson, MD, discusses serum BCMA and markers for predicting outcomes and monitoring disease in patients with multiple myeloma.

Findings speak to the need of cultural, racial, and ethnic inclusion when designing breast cancer trials and developing patient-reported outcome measures.

Inavolisib-based therapy reaches the primary end point of the phase 3 INAVO120 study among patients with PIK3CA-mutated breast cancer.

A nurse practitioner discusses the importance of compassionate end-of-life care discussions.

Consolidative hematopoietic cell transplantation also confers improved progression-free survival among those with relapsed/refractory B-ALL.

Treatment with (Z)-endoxifen yielded no changes in hematological safety tests among patients enrolled on the phase 2 KARISMA-Endoxifen study.

Extended lymphadenectomy did not improve DFS or OS, and led to a higher incidence of perioperative morbidity and mortality.

Updated OS findings from the PERLA trial showed continued success with dostarlimab plus chemotherapy in patients with advanced non–small cell lung cancer.